Journal Logo

Articles by R. Fanin

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP: PF695

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3:302, June 2019.

MULTI-CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS: PF758

Castagna, L.; Dodero, A.; Patriarca, F.; More

HemaSphere. 3:333, June 2019.

CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB: PB1930

Tiribelli, M.; Bonifacio, M.; Binotto, G.; More

HemaSphere. 3:877-878, June 2019.